Pay in 4 interest-free payments of $5.71 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Phase 2 trial results (48 weeks, adults with obesity): 1 mg dose: 7.2% body weight loss 4 mg dose: 12.9% body weight loss 8 mg dose: 17.3% body weight loss 12 mg dose: 24.2% body weight loss Placebo: 1.6% body weight loss Phase 3 TRIUMPH-4 results: 9 mg dose: 20.0% body weight loss (22.9 kg / 50.5 lbs) 12 mg dose: 23.7% body weight loss (27.2 kg / 60.0 lbs) Placebo: 4.6% body weight loss In a separate phase 3 analysis, retatrutide at the highest dose achieved up to 28.7% weight loss
Not exactly and that's okay
doi: 10.3389/fonc.2022.891652 Received 09 March 2022 Accepted 10 May 2022 Published 23 June 2022 Volume 12 - 2022 Edited by Milica Pei, University of Belgrade, Serbia Reviewed by Hodaka Fujii, Hirosaki University, Japan
Their clinical value lies not in any single endpoint, but in the capacity to concurrently address the cardiovascular, renal, and metabolic risk factors that commonly coexist in complex individuals
Emerging Polynucleotide and hydrolyzed-DNA treatments for skin quality
